Edgewise Therapeutics downgraded at Scotiabank on heart disease trial results
Source: SeekingAlpha
2025-04-03 11:10:25 ET
More on Edgewise Therapeutics
- Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On
- Edgewise Therapeutics: More Expensive Now, But Much More Derisked
- Biggest stock movers Wednesday: NCNO, TTEC, EWTX, BB, ANGO and more
- Cytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapy
- Seeking Alpha’s Quant Rating on Edgewise Therapeutics
Read the full article on Seeking Alpha
For further details see:
Edgewise Therapeutics downgraded at Scotiabank on heart disease trial results
Edgewise Therapeutics Inc.
NASDAQ: EWTX
EWTX Trading
15.75% G/L:
$39.055 Last:
2,691,761 Volume:
$40.60 Open:
EWTX Latest News
June 01, 2026 08:30:00 am
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
EWTX Stock Data
$3,280,862,770
54,628,112
N/A
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Boulder
